Steven Rubin Acquires 10,000 Shares of Entera Bio (NASDAQ:ENTX) Stock

Entera Bio Ltd. (NASDAQ:ENTX) Director Steven Rubin bought 10,000 shares of the stock in a transaction dated Monday, February 9th. The stock was bought at an average cost of $1.20 per share, with a total value of $12,000.00. Following the purchase, the director owned 10,000 shares in the company, valued at $12,000. The trade was a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Entera Bio Price Performance

ENTX opened at $1.52 on Friday. The stock’s 50 day simple moving average is $1.69 and its 200 day simple moving average is $2.03. The firm has a market cap of $69.71 million, a price-to-earnings ratio of -6.08 and a beta of 1.84. Entera Bio Ltd. has a 1 year low of $1.00 and a 1 year high of $3.22.

Entera Bio (NASDAQ:ENTX) last released its quarterly earnings data on Friday, November 14th. The company reported ($0.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.02. As a group, sell-side analysts anticipate that Entera Bio Ltd. will post -0.28 EPS for the current year.

Analyst Ratings Changes

ENTX has been the subject of a number of analyst reports. HC Wainwright reiterated a “buy” rating and set a $10.00 target price on shares of Entera Bio in a report on Monday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Entera Bio in a research report on Thursday, January 22nd. Finally, Wall Street Zen raised Entera Bio to a “sell” rating in a research note on Saturday, December 27th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Entera Bio has a consensus rating of “Hold” and a consensus price target of $10.00.

Hedge Funds Weigh In On Entera Bio

A number of institutional investors have recently bought and sold shares of the stock. Bessemer Group Inc. bought a new stake in Entera Bio during the 2nd quarter valued at approximately $268,000. Citadel Advisors LLC raised its position in shares of Entera Bio by 243.0% in the 3rd quarter. Citadel Advisors LLC now owns 39,978 shares of the company’s stock worth $77,000 after acquiring an additional 28,322 shares in the last quarter. HighTower Advisors LLC lifted its stake in shares of Entera Bio by 137.8% in the 4th quarter. HighTower Advisors LLC now owns 43,140 shares of the company’s stock valued at $84,000 after purchasing an additional 25,000 shares during the period. Renaissance Technologies LLC boosted its position in shares of Entera Bio by 22.2% during the fourth quarter. Renaissance Technologies LLC now owns 108,001 shares of the company’s stock valued at $210,000 after purchasing an additional 19,601 shares in the last quarter. Finally, Jane Street Group LLC grew its stake in Entera Bio by 142.6% in the fourth quarter. Jane Street Group LLC now owns 74,064 shares of the company’s stock worth $144,000 after purchasing an additional 43,536 shares during the period. 14.11% of the stock is owned by institutional investors.

Key Headlines Impacting Entera Bio

Here are the key news stories impacting Entera Bio this week:

• Positive Sentiment: Multiple insiders (CEO and several board members, including the Chairman) made open‑market purchases — a signal of management confidence in the pipeline, especially EB613 (oral PTH) and other N‑Tab® programs. Press release and disclosures are here. Open-Market Purchases Press Release
• Positive Sentiment: Director purchases disclosed via SEC filings — Steven Rubin (10,000 shares at ~$1.20) and Sean Ellis (18,000 shares at ~$1.24) — provide verifiable insider buying. SEC filings: Rubin and Ellis. Rubin SEC Filing Ellis SEC Filing
• Positive Sentiment: HC Wainwright reiterated a Buy rating (supports upside narrative and may attract growth/bio investors). HC Wainwright Coverage
• Neutral Sentiment: Retail/media coverage highlighted insider buys and optimistic retail sentiment, which can amplify volatility but doesn’t guarantee sustained buying. (MSN coverage). MSN Article
• Neutral Sentiment: Reported short‑interest entries in feeds are inconsistent/zero (NaN increases) — data appears unreliable and does not provide a clear short‑pressure signal. Monitor official exchange short‑interest reports for clarity.
• Negative Sentiment: Despite the insider buying and a Buy rating, shares are trading lower today — likely driven by limited liquidity (small market cap), mixed institutional moves (some funds reduced positions previously), and mixed analyst coverage (Buy and Sell ratings produce a Hold consensus), which can produce short‑term selling pressure.

Entera Bio Company Profile

Entera Bio, Inc is a clinical‐stage biopharmaceutical company pioneering the development of orally delivered peptide therapeutics. Utilizing its proprietary oral delivery platform, Entera Bio seeks to overcome the challenges of gastrointestinal absorption for large peptide molecules. The technology is designed to facilitate transit across the intestinal epithelium while preserving peptide structure and bioactivity, offering the potential for daily oral dosing in lieu of injectable formulations.

The company’s lead candidate, EB613, is an oral parathyroid hormone (PTH) analog under investigation for the treatment of osteoporosis.